



Assembly Biosciences, Inc.
Investor Relations Department
787 7th Avenue 48th Floor
New York, NY 10019
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: ASMB

Last Trade:	25.48
Trade Time:	3:25 PM ET May 24, 2017
Change:	1.38 (+5.726%)
Day Range	23.64 - 25.76
52-Week Range	5.00 - 28.18
Volume	27,886

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Assembly Biosciences, Inc. (Nasdaq: ASMB) is a public biotechnology company advancing a new class of oral biologic drugs for addressing the gut microbiome and novel approaches to discovering drugs for the treatment of hepatitis B virus (HBV) infection.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Feb 21, 2017

[Assembly Biosciences Announces the Closing and Early Termination of Hart-Scott-Rodino Waiting Period for License of Microbiome Gastrointestinal Development Programs to Allergan](#)

Feb 16, 2017

[Assembly Biosciences Announces Successful Completion of ABI-H0731 Phase 1a Trial and Upcoming Conference Presentations](#)

Jan 9, 2017

[Allergan Enters Into Licensing Agreement with Assembly Biosciences to Obtain Worldwide Rights to Microbiome Gastrointestinal Development Programs](#)

Nov 11, 2016

[Assembly Biosciences to Present Data on ABI-H0731 at AASLD 2016 Liver Meeting](#)

Nov 9, 2016

[Assembly Biosciences Initiates Phase 1 Clinical Program of ABI-H0731 for Treatment of Chronic Hepatitis B Virus Infection](#)

Upcoming Events [\[View all \]](#)

Jun 7, 2017 10:00 AM ET

[Jefferies 2017 Global Healthcare Conference](#)

Financials [\[View all \]](#)

[Third Quarter Financial Results](#)

Mar 2, 2017

[Annual Report \(10-K\)](#)

Apr 21, 2017

[Proxy Statement \(DEF 14A\)](#)

May 8, 2017

[Quarterly Report \(10-Q\)](#)

Nov 9, 2016

[Quarterly Report \(10-Q\)](#)

Aug 9, 2016

[Quarterly Report \(10-Q\)](#)